Display options
Cite
Tkac J, Gajdosova V, Hroncekova S, et al. Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Interface Focus. 2019;9(2):20180077doi: 10.1098/rsfs.2018.0077.
Tkac, J., Gajdosova, V., Hroncekova, S., Bertok, T., Hires, M., Jane, E., Lorencova, L., & Kasak, P. (2019). Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Interface focus, 9(2), 20180077. https://doi.org/10.1098/rsfs.2018.0077
Tkac, Jan, et al. "Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer." Interface focus vol. 9,2 (2019): 20180077. doi: https://doi.org/10.1098/rsfs.2018.0077
Tkac J, Gajdosova V, Hroncekova S, Bertok T, Hires M, Jane E, Lorencova L, Kasak P. Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Interface Focus. 2019 Apr 06;9(2):20180077. doi: 10.1098/rsfs.2018.0077. Epub 2019 Feb 15. PMID: 30842876; PMCID: PMC6388024.
Copy Download .nbib Format: NLM
Share it on

Interface Focus. 2019 Apr 06;9(2):20180077. doi: 10.1098/rsfs.2018.0077. Epub 2019 Feb 15.

Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer.

Interface focus

Jan Tkac, Veronika Gajdosova, Stefania Hroncekova, Tomas Bertok, Michal Hires, Eduard Jane, Lenka Lorencova, Peter Kasak

Affiliations

  1. Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 84538 Bratislava, Slovakia.
  2. Glycanostics Ltd, Dubravska cesta 9, 84538 Bratislava, Slovakia.
  3. Center for Advanced Materials, Qatar University, Doha 2713, Qatar.

PMID: 30842876 PMCID: PMC6388024 DOI: 10.1098/rsfs.2018.0077

Abstract

The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).

Keywords: biomarkers; diagnostics; glycans; lectins; prostate cancer; prostate-specific antigen

Conflict of interest statement

We declare we have no competing interests.

References

  1. Clin Biochem. 2003 Jul;36(5):373-6 - PubMed
  2. Nat Methods. 2007 May;4(5):437-44 - PubMed
  3. J Proteome Res. 2009 Feb;8(2):613-9 - PubMed
  4. J Proteome Res. 2009 Feb;8(2):620-30 - PubMed
  5. Glycobiology. 2010 Jan;20(4):452-60 - PubMed
  6. Clin Chim Acta. 2010 Dec 14;411(23-24):1935-9 - PubMed
  7. Anal Chem. 2011 Jan 1;83(1):240-5 - PubMed
  8. Anal Chem. 2011 Nov 15;83(22):8509-16 - PubMed
  9. J Mol Biol. 2011 Dec 9;414(4):530-44 - PubMed
  10. Clin Chim Acta. 2012 Oct 9;413(19-20):1500-5 - PubMed
  11. Ann Intern Med. 2012 Jul 17;157(2):120-34 - PubMed
  12. Nat Rev Urol. 2013 Feb;10(2):99-107 - PubMed
  13. Biochem Biophys Res Commun. 2014 Jun 13;448(4):390-6 - PubMed
  14. Prostate. 2014 Jul;74(10):1059-67 - PubMed
  15. Expert Rev Mol Diagn. 2014 Jul;14(6):713-22 - PubMed
  16. Biol Chem. 2014 Sep;395(9):959-76 - PubMed
  17. Biotechniques. 2014 Sep 01;57(3):143-9 - PubMed
  18. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  19. Anal Chem. 2015 Feb 3;87(3):1797-803 - PubMed
  20. Theranostics. 2015 Jan 01;5(3):267-76 - PubMed
  21. Annu Rev Pathol. 2015;10:473-510 - PubMed
  22. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  23. Adv Cancer Res. 2015;126:345-82 - PubMed
  24. J Proteome Res. 2015 Jul 2;14(7):2872-83 - PubMed
  25. Langmuir. 2015 Jun 30;31(25):7148-57 - PubMed
  26. Nat Rev Cancer. 2015 Sep;15(9):540-55 - PubMed
  27. Biosens Bioelectron. 2016 May 15;79:313-9 - PubMed
  28. Int J Biol Macromol. 2016 May;86:468-80 - PubMed
  29. Biochim Biophys Acta. 2016 Aug;1860(8):1676-87 - PubMed
  30. Oncotarget. 2016 Jun 7;7(23):35478-89 - PubMed
  31. Dis Markers. 2016;2016:8915809 - PubMed
  32. Theranostics. 2016 May 24;6(8):1190-204 - PubMed
  33. Oncotarget. 2016 Aug 30;7(35):56643-56649 - PubMed
  34. Anal Chim Acta. 2016 Aug 31;934:72-9 - PubMed
  35. Nat Immunol. 2016 Nov;17(11):1273-1281 - PubMed
  36. Int J Clin Oncol. 2017 Apr;22(2):214-221 - PubMed
  37. Electrophoresis. 2017 Jan;38(1):162-189 - PubMed
  38. Clin Biochem. 2017 Jan;50(1-2):54-61 - PubMed
  39. Med Res Rev. 2017 May;37(3):514-626 - PubMed
  40. Biotechnol Adv. 2017 Mar - Apr;35(2):135-149 - PubMed
  41. Nat Rev Urol. 2017 Jan;14(1):26-37 - PubMed
  42. Int J Mol Sci. 2017 Jan 26;18(2): - PubMed
  43. Nat Chem Biol. 2017 Apr;13(4):415-424 - PubMed
  44. Int J Mol Sci. 2017 Feb 22;18(2): - PubMed
  45. Int J Mol Sci. 2017 Apr 17;18(4):null - PubMed
  46. Clin Chim Acta. 2017 Jul;470:97-102 - PubMed
  47. Nat Rev Urol. 2017 Aug;14(8):457-458 - PubMed
  48. Sci Rep. 2017 Jun 16;7(1):3733 - PubMed
  49. Anal Chem. 2018 Jan 2;90(1):208-224 - PubMed
  50. Oncotarget. 2017 Aug 16;8(44):76987-76999 - PubMed
  51. Mikrochim Acta. 2017 Jul 14;184(9):3049-3067 - PubMed
  52. Nat Chem Biol. 2018 Jan;14(1):65-71 - PubMed
  53. Expert Rev Proteomics. 2018 Feb;15(2):183-190 - PubMed
  54. Science. 2018 Feb 23;359(6378):926-930 - PubMed
  55. Nat Rev Immunol. 2018 Mar;18(3):204-211 - PubMed
  56. Clin Chim Acta. 2018 May;480:1-8 - PubMed
  57. Clin Chim Acta. 2018 Jun;481:49-55 - PubMed
  58. Front Oncol. 2018 Feb 23;8:39 - PubMed
  59. Glycoconj J. 2018 Apr;35(2):139-160 - PubMed
  60. JAMA. 2018 May 8;319(18):1901-1913 - PubMed
  61. Front Oncol. 2018 May 28;8:174 - PubMed
  62. Mol Oncol. 2018 Sep;12(9):1513-1525 - PubMed
  63. Biol Chem. 2018 Sep 25;399(9):1009-1022 - PubMed
  64. Curr Med Chem. 2018 Sep 13;: - PubMed
  65. Expert Rev Proteomics. 2018 Nov 18;:1-12 - PubMed

Publication Types